Anbio Biotechnology (NNNN) director Hartzler files Form 3

Rhea-AI Filing Summary

Anbio Biotechnology director Hartzler Nancy filed a Form 3 insider report. The filing identifies her as a director of Anbio Biotechnology (ticker NNNN) and shows no reported transactions in company securities, with zero buys, zero sells, and no derivative exercises recorded.

Key Figures

Buy transactions: 0 transactions Sell transactions: 0 transactions Derivative exercises: 0 transactions +1 more

4 metrics

Buy transactions 0 transactions Form 3 transactionSummary buyCount

Sell transactions 0 transactions Form 3 transactionSummary sellCount

Derivative exercises 0 transactions Form 3 transactionSummary exerciseCount

Net buy/sell direction neutral Form 3 transactionSummary netBuySellDirection

Key Terms

Form 3, reportingPersons, derivativeTransactionCount

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reportingPersons regulatory

""reportingPersons": ["

derivativeTransactionCount financial

""derivativeTransactionCount": 0,"

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hartzler Nancy

(Last) (First) (Middle)

FRIEDRICH-EBERT-ANLAGE 35-37

(Street)

FRANKFURT AM MAIN 60327

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Anbio Biotechnology [ NNNN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Nancy Hartzler	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Anbio Biotechnology (NNNN) Form 3 for Hartzler Nancy show?

The Form 3 lists Hartzler Nancy as a director of Anbio Biotechnology and reporting person for this issuer. It shows no reported insider transactions, with zero buys, zero sells, and no derivative exercises or gifts disclosed in the summary data.

Are there any insider stock purchases or sales in the Anbio Biotechnology (NNNN) Form 3?

No insider stock purchases or sales are reported in this Form 3. The transaction summary fields show buyCount and sellCount as zero, along with zero exercise transactions and no other types of insider trades listed for Hartzler Nancy.

Does the Anbio Biotechnology (NNNN) Form 3 report any derivative securities activity?

The Form 3 reports no derivative securities activity for Hartzler Nancy. The derivativeTransactionCount is zero, and the derivativeSummary section is empty, indicating no listed option, warrant, or other derivative positions or related transactions in this filing.

What insider role is disclosed for Hartzler Nancy in the Anbio Biotechnology (NNNN) Form 3?

The filing identifies Hartzler Nancy as a director of Anbio Biotechnology. She is not shown as an officer or ten percent owner in the structured data, which marks her as a director and reporting person without other insider roles indicated.

Does the Anbio Biotechnology (NNNN) Form 3 include any gifts or tax-withholding transactions?

The Form 3 shows no gifts or tax-withholding transactions for Hartzler Nancy. The transaction summary lists giftCount and taxWithholdingCount as zero, and there are no related entries in the transactions or derivative sections of the report.